nodes	percent_of_prediction	percent_of_DWPC	metapath
Orlistat—obesity—polycystic ovary syndrome	0.495	0.614	CtDrD
Orlistat—type 2 diabetes mellitus—polycystic ovary syndrome	0.311	0.386	CtDrD
Orlistat—LIPF—pituitary gland—polycystic ovary syndrome	0.00473	0.0716	CbGeAlD
Orlistat—Reaction gastrointestinal—Metformin—polycystic ovary syndrome	0.00306	0.0904	CcSEcCtD
Orlistat—DAGLB—adipose tissue—polycystic ovary syndrome	0.00235	0.0356	CbGeAlD
Orlistat—ABHD16A—adrenal cortex—polycystic ovary syndrome	0.00222	0.0336	CbGeAlD
Orlistat—DAGLB—adrenal gland—polycystic ovary syndrome	0.00211	0.032	CbGeAlD
Orlistat—PLA2G7—endometrium—polycystic ovary syndrome	0.00211	0.0319	CbGeAlD
Orlistat—ABHD12—adrenal cortex—polycystic ovary syndrome	0.00208	0.0315	CbGeAlD
Orlistat—Appetite absent—Metformin—polycystic ovary syndrome	0.00205	0.0606	CcSEcCtD
Orlistat—ABHD16A—endometrium—polycystic ovary syndrome	0.00198	0.03	CbGeAlD
Orlistat—DAGLB—female gonad—polycystic ovary syndrome	0.00197	0.0298	CbGeAlD
Orlistat—PLA2G7—pituitary gland—polycystic ovary syndrome	0.00191	0.0289	CbGeAlD
Orlistat—PLA2G7—adipose tissue—polycystic ovary syndrome	0.0019	0.0288	CbGeAlD
Orlistat—ABHD12—endometrium—polycystic ovary syndrome	0.00185	0.0281	CbGeAlD
Orlistat—ABHD16A—pituitary gland—polycystic ovary syndrome	0.00179	0.0271	CbGeAlD
Orlistat—ABHD16A—adipose tissue—polycystic ovary syndrome	0.00178	0.027	CbGeAlD
Orlistat—Gastrointestinal symptom NOS—Metformin—polycystic ovary syndrome	0.00174	0.0513	CcSEcCtD
Orlistat—PLA2G7—adrenal gland—polycystic ovary syndrome	0.00171	0.0258	CbGeAlD
Orlistat—PNLIP—pituitary gland—polycystic ovary syndrome	0.00168	0.0254	CbGeAlD
Orlistat—ABHD12—pituitary gland—polycystic ovary syndrome	0.00168	0.0254	CbGeAlD
Orlistat—PNLIP—adipose tissue—polycystic ovary syndrome	0.00167	0.0253	CbGeAlD
Orlistat—ABHD12—adipose tissue—polycystic ovary syndrome	0.00167	0.0253	CbGeAlD
Orlistat—PLA2G7—female gonad—polycystic ovary syndrome	0.00159	0.0241	CbGeAlD
Orlistat—PLA2G7—vagina—polycystic ovary syndrome	0.00158	0.0239	CbGeAlD
Orlistat—Nail disorder—Metformin—polycystic ovary syndrome	0.00158	0.0465	CcSEcCtD
Orlistat—Upset stomach—Metformin—polycystic ovary syndrome	0.00156	0.046	CcSEcCtD
Orlistat—ABHD12—adrenal gland—polycystic ovary syndrome	0.0015	0.0227	CbGeAlD
Orlistat—ABHD16A—female gonad—polycystic ovary syndrome	0.00149	0.0226	CbGeAlD
Orlistat—ABHD16A—vagina—polycystic ovary syndrome	0.00148	0.0225	CbGeAlD
Orlistat—PLA2G7—endocrine gland—polycystic ovary syndrome	0.00148	0.0224	CbGeAlD
Orlistat—FASN—uterus—polycystic ovary syndrome	0.00143	0.0217	CbGeAlD
Orlistat—FASN—pituitary gland—polycystic ovary syndrome	0.00141	0.0213	CbGeAlD
Orlistat—FASN—adipose tissue—polycystic ovary syndrome	0.0014	0.0212	CbGeAlD
Orlistat—ABHD12—female gonad—polycystic ovary syndrome	0.0014	0.0212	CbGeAlD
Orlistat—PNLIP—female gonad—polycystic ovary syndrome	0.0014	0.0212	CbGeAlD
Orlistat—ABHD12—vagina—polycystic ovary syndrome	0.00139	0.021	CbGeAlD
Orlistat—PNLIP—endocrine gland—polycystic ovary syndrome	0.0013	0.0197	CbGeAlD
Orlistat—FASN—adrenal gland—polycystic ovary syndrome	0.00126	0.0191	CbGeAlD
Orlistat—Blood disorder—Metformin—polycystic ovary syndrome	0.00122	0.0361	CcSEcCtD
Orlistat—FASN—female gonad—polycystic ovary syndrome	0.00117	0.0178	CbGeAlD
Orlistat—FASN—vagina—polycystic ovary syndrome	0.00117	0.0177	CbGeAlD
Orlistat—CYP3A4—urine—polycystic ovary syndrome	0.00104	0.0158	CbGeAlD
Orlistat—PLA2G4A—adrenal cortex—polycystic ovary syndrome	0.000838	0.0127	CbGeAlD
Orlistat—Hypoglycaemia—Metformin—polycystic ovary syndrome	0.00076	0.0224	CcSEcCtD
Orlistat—PLA2G4A—endometrium—polycystic ovary syndrome	0.000748	0.0113	CbGeAlD
Orlistat—Abdominal pain upper—Metformin—polycystic ovary syndrome	0.000678	0.02	CcSEcCtD
Orlistat—PLA2G4A—pituitary gland—polycystic ovary syndrome	0.000677	0.0103	CbGeAlD
Orlistat—PLA2G4A—adipose tissue—polycystic ovary syndrome	0.000674	0.0102	CbGeAlD
Orlistat—Breast disorder—Metformin—polycystic ovary syndrome	0.00067	0.0198	CcSEcCtD
Orlistat—Cramp muscle—Metformin—polycystic ovary syndrome	0.000668	0.0197	CcSEcCtD
Orlistat—Abdominal distension—Metformin—polycystic ovary syndrome	0.000646	0.0191	CcSEcCtD
Orlistat—Influenza—Metformin—polycystic ovary syndrome	0.000641	0.0189	CcSEcCtD
Orlistat—Pancreatitis—Metformin—polycystic ovary syndrome	0.000629	0.0186	CcSEcCtD
Orlistat—Sweating increased—Metformin—polycystic ovary syndrome	0.000625	0.0184	CcSEcCtD
Orlistat—Abdominal discomfort—Metformin—polycystic ovary syndrome	0.000615	0.0181	CcSEcCtD
Orlistat—PLA2G4A—adrenal gland—polycystic ovary syndrome	0.000605	0.00916	CbGeAlD
Orlistat—Upper respiratory tract infection—Metformin—polycystic ovary syndrome	0.000596	0.0176	CcSEcCtD
Orlistat—Infestation—Metformin—polycystic ovary syndrome	0.000572	0.0169	CcSEcCtD
Orlistat—Infestation NOS—Metformin—polycystic ovary syndrome	0.000572	0.0169	CcSEcCtD
Orlistat—PLA2G4A—female gonad—polycystic ovary syndrome	0.000564	0.00854	CbGeAlD
Orlistat—PLA2G4A—vagina—polycystic ovary syndrome	0.000561	0.00849	CbGeAlD
Orlistat—Neuropathy peripheral—Metformin—polycystic ovary syndrome	0.00056	0.0165	CcSEcCtD
Orlistat—Hepatobiliary disease—Metformin—polycystic ovary syndrome	0.000541	0.016	CcSEcCtD
Orlistat—PLA2G4A—endocrine gland—polycystic ovary syndrome	0.000525	0.00794	CbGeAlD
Orlistat—Hepatitis—Metformin—polycystic ovary syndrome	0.000513	0.0152	CcSEcCtD
Orlistat—Oedema peripheral—Metformin—polycystic ovary syndrome	0.000506	0.0149	CcSEcCtD
Orlistat—Immune system disorder—Metformin—polycystic ovary syndrome	0.000464	0.0137	CcSEcCtD
Orlistat—Mediastinal disorder—Metformin—polycystic ovary syndrome	0.000463	0.0137	CcSEcCtD
Orlistat—Malnutrition—Metformin—polycystic ovary syndrome	0.000447	0.0132	CcSEcCtD
Orlistat—Flatulence—Metformin—polycystic ovary syndrome	0.00044	0.013	CcSEcCtD
Orlistat—Dysgeusia—Metformin—polycystic ovary syndrome	0.000438	0.0129	CcSEcCtD
Orlistat—Muscle spasms—Metformin—polycystic ovary syndrome	0.00043	0.0127	CcSEcCtD
Orlistat—Vision blurred—Metformin—polycystic ovary syndrome	0.000421	0.0124	CcSEcCtD
Orlistat—Ill-defined disorder—Metformin—polycystic ovary syndrome	0.000415	0.0122	CcSEcCtD
Orlistat—Malaise—Metformin—polycystic ovary syndrome	0.000403	0.0119	CcSEcCtD
Orlistat—Palpitations—Metformin—polycystic ovary syndrome	0.000395	0.0117	CcSEcCtD
Orlistat—Chest pain—Metformin—polycystic ovary syndrome	0.00038	0.0112	CcSEcCtD
Orlistat—Myalgia—Metformin—polycystic ovary syndrome	0.00038	0.0112	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Metformin—polycystic ovary syndrome	0.000378	0.0112	CcSEcCtD
Orlistat—Discomfort—Metformin—polycystic ovary syndrome	0.000376	0.0111	CcSEcCtD
Orlistat—Oedema—Metformin—polycystic ovary syndrome	0.000365	0.0108	CcSEcCtD
Orlistat—Infection—Metformin—polycystic ovary syndrome	0.000362	0.0107	CcSEcCtD
Orlistat—Nervous system disorder—Metformin—polycystic ovary syndrome	0.000358	0.0106	CcSEcCtD
Orlistat—Skin disorder—Metformin—polycystic ovary syndrome	0.000354	0.0105	CcSEcCtD
Orlistat—Hyperhidrosis—Metformin—polycystic ovary syndrome	0.000353	0.0104	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Metformin—polycystic ovary syndrome	0.000332	0.00981	CcSEcCtD
Orlistat—Paraesthesia—Metformin—polycystic ovary syndrome	0.000327	0.00967	CcSEcCtD
Orlistat—Dyspepsia—Metformin—polycystic ovary syndrome	0.000321	0.00948	CcSEcCtD
Orlistat—Decreased appetite—Metformin—polycystic ovary syndrome	0.000317	0.00936	CcSEcCtD
Orlistat—Gastrointestinal disorder—Metformin—polycystic ovary syndrome	0.000315	0.00929	CcSEcCtD
Orlistat—Fatigue—Metformin—polycystic ovary syndrome	0.000314	0.00928	CcSEcCtD
Orlistat—Feeling abnormal—Metformin—polycystic ovary syndrome	0.0003	0.00887	CcSEcCtD
Orlistat—Gastrointestinal pain—Metformin—polycystic ovary syndrome	0.000298	0.0088	CcSEcCtD
Orlistat—Urticaria—Metformin—polycystic ovary syndrome	0.00029	0.00855	CcSEcCtD
Orlistat—Abdominal pain—Metformin—polycystic ovary syndrome	0.000288	0.00851	CcSEcCtD
Orlistat—Asthenia—Metformin—polycystic ovary syndrome	0.000262	0.00772	CcSEcCtD
Orlistat—Pruritus—Metformin—polycystic ovary syndrome	0.000258	0.00762	CcSEcCtD
Orlistat—Diarrhoea—Metformin—polycystic ovary syndrome	0.000249	0.00737	CcSEcCtD
Orlistat—Dizziness—Metformin—polycystic ovary syndrome	0.000241	0.00712	CcSEcCtD
Orlistat—Vomiting—Metformin—polycystic ovary syndrome	0.000232	0.00684	CcSEcCtD
Orlistat—Rash—Metformin—polycystic ovary syndrome	0.00023	0.00679	CcSEcCtD
Orlistat—Dermatitis—Metformin—polycystic ovary syndrome	0.00023	0.00678	CcSEcCtD
Orlistat—Headache—Metformin—polycystic ovary syndrome	0.000228	0.00674	CcSEcCtD
Orlistat—Nausea—Metformin—polycystic ovary syndrome	0.000217	0.00639	CcSEcCtD
Orlistat—CYP3A4—endocrine gland—polycystic ovary syndrome	0.000173	0.00262	CbGeAlD
Orlistat—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—polycystic ovary syndrome	3e-05	0.00032	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—FLT4—polycystic ovary syndrome	2.99e-05	0.000319	CbGpPWpGaD
Orlistat—CYP3A4—Tryptophan metabolism—CYP1A1—polycystic ovary syndrome	2.99e-05	0.000319	CbGpPWpGaD
Orlistat—FASN—Metabolism—CYP11A1—polycystic ovary syndrome	2.99e-05	0.000318	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—PDE3B—polycystic ovary syndrome	2.97e-05	0.000316	CbGpPWpGaD
Orlistat—FASN—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	2.96e-05	0.000316	CbGpPWpGaD
Orlistat—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—polycystic ovary syndrome	2.96e-05	0.000315	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—IGF1—polycystic ovary syndrome	2.93e-05	0.000312	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—ATF1—polycystic ovary syndrome	2.88e-05	0.000307	CbGpPWpGaD
Orlistat—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—polycystic ovary syndrome	2.88e-05	0.000307	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—CYP11A1—polycystic ovary syndrome	2.88e-05	0.000307	CbGpPWpGaD
Orlistat—FASN—Disease—TCF7L2—polycystic ovary syndrome	2.84e-05	0.000302	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—AKR1C2—polycystic ovary syndrome	2.83e-05	0.000301	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—TEAD2—polycystic ovary syndrome	2.83e-05	0.000301	CbGpPWpGaD
Orlistat—FASN—Metabolism—AKR1C3—polycystic ovary syndrome	2.82e-05	0.000301	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—TCF7L2—polycystic ovary syndrome	2.81e-05	0.000299	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—GNAS—polycystic ovary syndrome	2.8e-05	0.000298	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—GNAS—polycystic ovary syndrome	2.8e-05	0.000298	CbGpPWpGaD
Orlistat—FASN—Disease—SLC2A4—polycystic ovary syndrome	2.79e-05	0.000297	CbGpPWpGaD
Orlistat—PNLIP—Disease—MTHFR—polycystic ovary syndrome	2.79e-05	0.000297	CbGpPWpGaD
Orlistat—FASN—Metabolism—CYP17A1—polycystic ovary syndrome	2.78e-05	0.000296	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—GNAS—polycystic ovary syndrome	2.77e-05	0.000295	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—AKR1C3—polycystic ovary syndrome	2.72e-05	0.00029	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—PLAT—polycystic ovary syndrome	2.7e-05	0.000288	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—FSHR—polycystic ovary syndrome	2.7e-05	0.000288	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—CYP17A1—polycystic ovary syndrome	2.67e-05	0.000285	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—NCOR1—polycystic ovary syndrome	2.66e-05	0.000284	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—NCOR1—polycystic ovary syndrome	2.66e-05	0.000284	CbGpPWpGaD
Orlistat—FASN—Disease—PRL—polycystic ovary syndrome	2.66e-05	0.000284	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—NGFR—polycystic ovary syndrome	2.66e-05	0.000283	CbGpPWpGaD
Orlistat—PNLIP—Disease—IRS2—polycystic ovary syndrome	2.65e-05	0.000282	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—NCOR1—polycystic ovary syndrome	2.64e-05	0.000281	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—PRL—polycystic ovary syndrome	2.63e-05	0.000281	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—NRG1—polycystic ovary syndrome	2.61e-05	0.000279	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—NRG1—polycystic ovary syndrome	2.61e-05	0.000279	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—NPB—polycystic ovary syndrome	2.61e-05	0.000278	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—IGF1—polycystic ovary syndrome	2.61e-05	0.000278	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—AKT2—polycystic ovary syndrome	2.61e-05	0.000278	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—BCL2—polycystic ovary syndrome	2.56e-05	0.000273	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—CYP1A1—polycystic ovary syndrome	2.5e-05	0.000267	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—ADRB2—polycystic ovary syndrome	2.5e-05	0.000266	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—SERPINE1—polycystic ovary syndrome	2.48e-05	0.000264	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—ADRA1A—polycystic ovary syndrome	2.47e-05	0.000263	CbGpPWpGaD
Orlistat—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—polycystic ovary syndrome	2.43e-05	0.000259	CbGpPWpGaD
Orlistat—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—polycystic ovary syndrome	2.42e-05	0.000258	CbGpPWpGaD
Orlistat—FASN—Metabolism—TH—polycystic ovary syndrome	2.4e-05	0.000256	CbGpPWpGaD
Orlistat—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—polycystic ovary syndrome	2.38e-05	0.000254	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—ADRB3—polycystic ovary syndrome	2.38e-05	0.000254	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PNPLA2—polycystic ovary syndrome	2.37e-05	0.000252	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PLEKHG5—polycystic ovary syndrome	2.36e-05	0.000252	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—LHB—polycystic ovary syndrome	2.35e-05	0.000251	CbGpPWpGaD
Orlistat—FASN—Metabolism—SLC2A4—polycystic ovary syndrome	2.34e-05	0.000249	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—MTHFR—polycystic ovary syndrome	2.33e-05	0.000249	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—GNAS—polycystic ovary syndrome	2.32e-05	0.000247	CbGpPWpGaD
Orlistat—PNLIP—Disease—IRS1—polycystic ovary syndrome	2.31e-05	0.000247	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—GNRH1—polycystic ovary syndrome	2.3e-05	0.000245	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—SRD5A1—polycystic ovary syndrome	2.24e-05	0.000239	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—IRS2—polycystic ovary syndrome	2.24e-05	0.000239	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—IRS2—polycystic ovary syndrome	2.24e-05	0.000239	CbGpPWpGaD
Orlistat—FASN—Disease—NCOR1—polycystic ovary syndrome	2.23e-05	0.000238	CbGpPWpGaD
Orlistat—PNLIP—Disease—INS—polycystic ovary syndrome	2.22e-05	0.000236	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—NCOR1—polycystic ovary syndrome	2.21e-05	0.000235	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—SCT—polycystic ovary syndrome	2.2e-05	0.000235	CbGpPWpGaD
Orlistat—FASN—Metabolism—CYP19A1—polycystic ovary syndrome	2.2e-05	0.000234	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—LEP—polycystic ovary syndrome	2.19e-05	0.000234	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—LEP—polycystic ovary syndrome	2.19e-05	0.000234	CbGpPWpGaD
Orlistat—FASN—Disease—NRG1—polycystic ovary syndrome	2.19e-05	0.000233	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PTGER3—polycystic ovary syndrome	2.18e-05	0.000232	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—LHCGR—polycystic ovary syndrome	2.18e-05	0.000232	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—NRG1—polycystic ovary syndrome	2.17e-05	0.000231	CbGpPWpGaD
Orlistat—PNLIP—Disease—AKT2—polycystic ovary syndrome	2.14e-05	0.000228	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—STAR—polycystic ovary syndrome	2.14e-05	0.000228	CbGpPWpGaD
Orlistat—CYP3A4—Metapathway biotransformation—AKR1C1—polycystic ovary syndrome	2.12e-05	0.000226	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—CYP19A1—polycystic ovary syndrome	2.12e-05	0.000226	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—MTNR1B—polycystic ovary syndrome	2.1e-05	0.000224	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—GNAS—polycystic ovary syndrome	2.08e-05	0.000221	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PTAFR—polycystic ovary syndrome	2.04e-05	0.000217	CbGpPWpGaD
Orlistat—PNLIP—Disease—SERPINE1—polycystic ovary syndrome	2.04e-05	0.000217	CbGpPWpGaD
Orlistat—CYP3A4—Biological oxidations—SULT2A1—polycystic ovary syndrome	1.98e-05	0.000211	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—ADRA1D—polycystic ovary syndrome	1.98e-05	0.000211	CbGpPWpGaD
Orlistat—FASN—Disease—MTHFR—polycystic ovary syndrome	1.97e-05	0.00021	CbGpPWpGaD
Orlistat—FASN—Metabolism—GNAS—polycystic ovary syndrome	1.96e-05	0.000209	CbGpPWpGaD
Orlistat—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—polycystic ovary syndrome	1.96e-05	0.000209	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—IRS1—polycystic ovary syndrome	1.96e-05	0.000208	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—IRS1—polycystic ovary syndrome	1.96e-05	0.000208	CbGpPWpGaD
Orlistat—CYP3A4—Metapathway biotransformation—SULT2A1—polycystic ovary syndrome	1.95e-05	0.000208	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—ADRA1B—polycystic ovary syndrome	1.93e-05	0.000205	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—VEGFA—polycystic ovary syndrome	1.91e-05	0.000204	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—HMMR—polycystic ovary syndrome	1.91e-05	0.000203	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—PPARG—polycystic ovary syndrome	1.89e-05	0.000202	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—POMC—polycystic ovary syndrome	1.88e-05	0.000201	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—POMC—polycystic ovary syndrome	1.88e-05	0.000201	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—INHBB—polycystic ovary syndrome	1.88e-05	0.0002	CbGpPWpGaD
Orlistat—FASN—Disease—IRS2—polycystic ovary syndrome	1.88e-05	0.0002	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—INS—polycystic ovary syndrome	1.87e-05	0.0002	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—INS—polycystic ovary syndrome	1.87e-05	0.0002	CbGpPWpGaD
Orlistat—FASN—Metabolism—NCOR1—polycystic ovary syndrome	1.87e-05	0.000199	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—POMC—polycystic ovary syndrome	1.87e-05	0.000199	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—IRS2—polycystic ovary syndrome	1.86e-05	0.000198	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—INS—polycystic ovary syndrome	1.86e-05	0.000198	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—HSD3B1—polycystic ovary syndrome	1.82e-05	0.000194	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—LEP—polycystic ovary syndrome	1.82e-05	0.000194	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—IGF1—polycystic ovary syndrome	1.81e-05	0.000193	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—IGF1—polycystic ovary syndrome	1.81e-05	0.000193	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—AKT2—polycystic ovary syndrome	1.81e-05	0.000193	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—AKT2—polycystic ovary syndrome	1.81e-05	0.000193	CbGpPWpGaD
Orlistat—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—polycystic ovary syndrome	1.8e-05	0.000192	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—NCOR1—polycystic ovary syndrome	1.8e-05	0.000192	CbGpPWpGaD
Orlistat—FASN—Metabolism—CYP1A1—polycystic ovary syndrome	1.77e-05	0.000189	CbGpPWpGaD
Orlistat—CYP3A4—Biological oxidations—CYP11A1—polycystic ovary syndrome	1.75e-05	0.000187	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PDE3B—polycystic ovary syndrome	1.75e-05	0.000187	CbGpPWpGaD
Orlistat—CYP3A4—Metapathway biotransformation—CYP11A1—polycystic ovary syndrome	1.73e-05	0.000184	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.72e-05	0.000183	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.72e-05	0.000183	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—CYP1A1—polycystic ovary syndrome	1.71e-05	0.000182	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—VEGFA—polycystic ovary syndrome	1.7e-05	0.000182	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—LHB—polycystic ovary syndrome	1.66e-05	0.000177	CbGpPWpGaD
Orlistat—FASN—Metabolism—MTHFR—polycystic ovary syndrome	1.65e-05	0.000176	CbGpPWpGaD
Orlistat—FASN—Disease—IRS1—polycystic ovary syndrome	1.64e-05	0.000174	CbGpPWpGaD
Orlistat—CYP3A4—Metapathway biotransformation—AKR1C3—polycystic ovary syndrome	1.63e-05	0.000174	CbGpPWpGaD
Orlistat—CYP3A4—Biological oxidations—CYP17A1—polycystic ovary syndrome	1.63e-05	0.000174	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—HSD3B2—polycystic ovary syndrome	1.62e-05	0.000173	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—IRS1—polycystic ovary syndrome	1.62e-05	0.000173	CbGpPWpGaD
Orlistat—CYP3A4—Metapathway biotransformation—CYP17A1—polycystic ovary syndrome	1.61e-05	0.000171	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—FSHR—polycystic ovary syndrome	1.6e-05	0.00017	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—AKR1C1—polycystic ovary syndrome	1.57e-05	0.000168	CbGpPWpGaD
Orlistat—FASN—Disease—INS—polycystic ovary syndrome	1.57e-05	0.000167	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—POMC—polycystic ovary syndrome	1.56e-05	0.000166	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—GHRL—polycystic ovary syndrome	1.55e-05	0.000165	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—INS—polycystic ovary syndrome	1.55e-05	0.000165	CbGpPWpGaD
Orlistat—FASN—Disease—AKT2—polycystic ovary syndrome	1.52e-05	0.000162	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—IGF1—polycystic ovary syndrome	1.5e-05	0.00016	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—RACGAP1—polycystic ovary syndrome	1.5e-05	0.00016	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—AKT2—polycystic ovary syndrome	1.5e-05	0.00016	CbGpPWpGaD
Orlistat—CYP3A4—Phase 1 - Functionalization of compounds—POMC—polycystic ovary syndrome	1.46e-05	0.000156	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—ADRA1A—polycystic ovary syndrome	1.46e-05	0.000156	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—SULT2A1—polycystic ovary syndrome	1.45e-05	0.000154	CbGpPWpGaD
Orlistat—FASN—Disease—SERPINE1—polycystic ovary syndrome	1.44e-05	0.000153	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.43e-05	0.000152	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—FST—polycystic ovary syndrome	1.42e-05	0.000152	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—ADRB3—polycystic ovary syndrome	1.41e-05	0.00015	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—RRM2—polycystic ovary syndrome	1.4e-05	0.000149	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—LHB—polycystic ovary syndrome	1.39e-05	0.000148	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—IL6—polycystic ovary syndrome	1.39e-05	0.000148	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—IL6—polycystic ovary syndrome	1.39e-05	0.000148	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—GNRH1—polycystic ovary syndrome	1.36e-05	0.000145	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—YAP1—polycystic ovary syndrome	1.35e-05	0.000144	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—IGF1—polycystic ovary syndrome	1.34e-05	0.000143	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—AKT2—polycystic ovary syndrome	1.34e-05	0.000143	CbGpPWpGaD
Orlistat—FASN—Metabolism—PPARG—polycystic ovary syndrome	1.34e-05	0.000143	CbGpPWpGaD
Orlistat—FASN—Metabolism—POMC—polycystic ovary syndrome	1.32e-05	0.000141	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—AKR1C1—polycystic ovary syndrome	1.31e-05	0.00014	CbGpPWpGaD
Orlistat—FASN—Metabolism—INS—polycystic ovary syndrome	1.31e-05	0.00014	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—SCT—polycystic ovary syndrome	1.3e-05	0.000139	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—NAMPT—polycystic ovary syndrome	1.3e-05	0.000138	CbGpPWpGaD
Orlistat—CYP3A4—Biological oxidations—CYP19A1—polycystic ovary syndrome	1.29e-05	0.000138	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	1.29e-05	0.000137	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—ADRB2—polycystic ovary syndrome	1.28e-05	0.000137	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CYP11A1—polycystic ovary syndrome	1.28e-05	0.000137	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—SERPINE1—polycystic ovary syndrome	1.28e-05	0.000136	CbGpPWpGaD
Orlistat—CYP3A4—Metapathway biotransformation—CYP19A1—polycystic ovary syndrome	1.27e-05	0.000136	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	1.27e-05	0.000136	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MTNR1B—polycystic ovary syndrome	1.24e-05	0.000132	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—FGF18—polycystic ovary syndrome	1.22e-05	0.00013	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—AKR1C3—polycystic ovary syndrome	1.21e-05	0.000129	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—RBP4—polycystic ovary syndrome	1.21e-05	0.000129	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CYP17A1—polycystic ovary syndrome	1.19e-05	0.000127	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—GNAS—polycystic ovary syndrome	1.19e-05	0.000127	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.18e-05	0.000126	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.18e-05	0.000126	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—YAP1—polycystic ovary syndrome	1.13e-05	0.00012	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—GAB1—polycystic ovary syndrome	1.11e-05	0.000119	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—INSR—polycystic ovary syndrome	1.06e-05	0.000114	CbGpPWpGaD
Orlistat—CYP3A4—Biological oxidations—CYP1A1—polycystic ovary syndrome	1.04e-05	0.000111	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—TH—polycystic ovary syndrome	1.03e-05	0.00011	CbGpPWpGaD
Orlistat—CYP3A4—Metapathway biotransformation—CYP1A1—polycystic ovary syndrome	1.03e-05	0.000109	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—AKR1C3—polycystic ovary syndrome	1.01e-05	0.000108	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—SLC2A4—polycystic ovary syndrome	1e-05	0.000107	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TNRC6B—polycystic ovary syndrome	9.96e-06	0.000106	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PGR—polycystic ovary syndrome	9.86e-06	0.000105	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—VEGFA—polycystic ovary syndrome	9.8e-06	0.000104	CbGpPWpGaD
Orlistat—PNLIP—Disease—IL6—polycystic ovary syndrome	9.68e-06	0.000103	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CYP19A1—polycystic ovary syndrome	9.43e-06	0.0001	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PLAT—polycystic ovary syndrome	9.17e-06	9.77e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—GHRL—polycystic ovary syndrome	9.17e-06	9.77e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—NMNAT3—polycystic ovary syndrome	9.15e-06	9.76e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—VEGFA—polycystic ovary syndrome	8.78e-06	9.36e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—ATF1—polycystic ovary syndrome	8.74e-06	9.32e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TCF7L2—polycystic ovary syndrome	8.53e-06	9.09e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—GNAS—polycystic ovary syndrome	8.41e-06	8.97e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—SUOX—polycystic ovary syndrome	8.37e-06	8.92e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—LPCAT2—polycystic ovary syndrome	8.37e-06	8.92e-05	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—IL6—polycystic ovary syndrome	8.18e-06	8.72e-05	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—IL6—polycystic ovary syndrome	8.18e-06	8.72e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—NGFR—polycystic ovary syndrome	8.07e-06	8.6e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—POMC—polycystic ovary syndrome	8.02e-06	8.55e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—NCOR1—polycystic ovary syndrome	8.02e-06	8.54e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PRL—polycystic ovary syndrome	8e-06	8.52e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ISYNA1—polycystic ovary syndrome	7.78e-06	8.3e-05	CbGpPWpGaD
Orlistat—CYP3A4—Biological oxidations—POMC—polycystic ovary syndrome	7.76e-06	8.27e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—AKT2—polycystic ovary syndrome	7.71e-06	8.22e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CYP1A1—polycystic ovary syndrome	7.6e-06	8.1e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—ADRB2—polycystic ovary syndrome	7.59e-06	8.09e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—MTHFR—polycystic ovary syndrome	7.08e-06	7.55e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—GNAS—polycystic ovary syndrome	7.04e-06	7.5e-05	CbGpPWpGaD
Orlistat—FASN—Disease—IL6—polycystic ovary syndrome	6.85e-06	7.3e-05	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—IL6—polycystic ovary syndrome	6.78e-06	7.23e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—NCOR1—polycystic ovary syndrome	6.7e-06	7.14e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—TEAD2—polycystic ovary syndrome	6.62e-06	7.05e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—AKR1C2—polycystic ovary syndrome	6.62e-06	7.05e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—NRG1—polycystic ovary syndrome	6.58e-06	7.01e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PPARG—polycystic ovary syndrome	5.74e-06	6.12e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—POMC—polycystic ovary syndrome	5.67e-06	6.04e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—IRS2—polycystic ovary syndrome	5.63e-06	6.01e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—INS—polycystic ovary syndrome	5.63e-06	6.01e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PNPLA2—polycystic ovary syndrome	5.55e-06	5.91e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—LEP—polycystic ovary syndrome	5.51e-06	5.88e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—SRD5A1—polycystic ovary syndrome	5.26e-06	5.6e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—STAR—polycystic ovary syndrome	5.02e-06	5.35e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—IRS1—polycystic ovary syndrome	4.92e-06	5.24e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—POMC—polycystic ovary syndrome	4.74e-06	5.05e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—INS—polycystic ovary syndrome	4.71e-06	5.02e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—IGF1—polycystic ovary syndrome	4.56e-06	4.86e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—AKT2—polycystic ovary syndrome	4.55e-06	4.85e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—HMMR—polycystic ovary syndrome	4.47e-06	4.76e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	4.33e-06	4.61e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—HSD3B1—polycystic ovary syndrome	4.26e-06	4.55e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—LHB—polycystic ovary syndrome	3.89e-06	4.14e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—HSD3B2—polycystic ovary syndrome	3.8e-06	4.05e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—AKR1C1—polycystic ovary syndrome	3.68e-06	3.92e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—IL6—polycystic ovary syndrome	3.48e-06	3.71e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—SULT2A1—polycystic ovary syndrome	3.39e-06	3.61e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—RRM2—polycystic ovary syndrome	3.28e-06	3.5e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—YAP1—polycystic ovary syndrome	3.16e-06	3.37e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—NAMPT—polycystic ovary syndrome	3.04e-06	3.24e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CYP11A1—polycystic ovary syndrome	3e-06	3.2e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.98e-06	3.17e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—AKR1C3—polycystic ovary syndrome	2.83e-06	3.02e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CYP17A1—polycystic ovary syndrome	2.79e-06	2.97e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—TH—polycystic ovary syndrome	2.41e-06	2.57e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—SLC2A4—polycystic ovary syndrome	2.35e-06	2.5e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CYP19A1—polycystic ovary syndrome	2.21e-06	2.35e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—IL6—polycystic ovary syndrome	2.06e-06	2.19e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GNAS—polycystic ovary syndrome	1.97e-06	2.1e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—NCOR1—polycystic ovary syndrome	1.88e-06	2e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CYP1A1—polycystic ovary syndrome	1.78e-06	1.9e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—MTHFR—polycystic ovary syndrome	1.66e-06	1.77e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PPARG—polycystic ovary syndrome	1.35e-06	1.43e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—POMC—polycystic ovary syndrome	1.33e-06	1.41e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—INS—polycystic ovary syndrome	1.32e-06	1.41e-05	CbGpPWpGaD
